Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Improve Sacituzumab Govitecan Tolerance With Atropine in Patients With Advanced Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer

NCT07367178 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT07367178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07367178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Improve Sacituzumab Govitecan Tolerance With Atropine in Patients With Advanced Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
January 31, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hr+/her2- breast cancer, advanced triple-negative breast cancer, breast cancer